Abstract: Disclosed are methods for lowering cholesterol and treating heart disease in an animal employing prenylchalcones or prenyllavonones. Such prenylchalcones or prenyllavonones may be derived from hops (humulus Lupulus L.), or produced synthetically. Representative prenylchalcones or prenyllavonones are: xanthohumol, xantho galenol, desmethylxanthohumol (2',4',6'-tetrahydroxy-3'-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocyclo xanthohumol, dehydrocyclo xanthohumol hydrate, 5'-prenyl xanthohumol, tetrahydro xanthohumol, 4'-O-5'-C-diprenyl xanthohumol, chalconaringenin, isoxanthohumol, 6-prenyl naringenin, 8-prenyl naringenin, 6,8-diprenyl naringenin, 4',6'-dimethoxy-2',4'-dihydroxy xanthohumol, 4'-O-methyl xanthohumol, 6-geranyl naringenin, 8-geranyl naringenin. The preferred prenylchalcone is xanthohumol.
METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA

FIELD OF THE INVENTION

This invention relates to therapeutic compositions and methods for treating elevated cholesterol and heart disease.

BACKGROUND OF THE INVENTION

Direct health care costs associated with cardiovascular disease exceed $100 billion per year in the United States alone and there are very few effective therapies available that treat more than one symptom or cause of coronary artery disease. Most of the drugs prescribed for heart disease treat one aspect of the disease such as elevated cholesterol, or blood pressure. Because insulin resistance and obesity are usually part of the same metabolic syndrome, therapeutic agents that attack the metabolic complications of cardiovascular disease, diabetes, and obesity would be of great value. The diabetic syndrome is usually accompanied by elevated levels of triglycerides and low levels of HDL cholesterol, a lipid profile that is considered to be one of dyslipidaemia, or a lipid profile associated with cardiovascular disease. Many patients with diagnosed coronary heart disease also have high cholesterol, in addition to low HDL and high triglycerides and fatty acids.

Many large prospective clinical trials have demonstrated that reducing cholesterol levels in blood is effective treatment for the primary and secondary prevention of heart disease and other complications of atherosclerosis.

Triglycerides are the major storage form of energy and are synthesized primarily in three tissues; the small intestine, liver, and adipocytes. The major functions of the molecule in these tissues are: (a) dietary fat absorption, (b) lipoprotein packaging of the de novo synthesized fatty acids, and (c) fat storage in adipose tissue. Free fatty acids are converted from dietary fat through the digestion process by pancreatic lipase. Some fatty acids are produced endogenously from dietary carbohydrate that is not utilized for energy.
production. This takes place primarily in the liver. Fatty acid synthesis is greatly 
elevated by glucose and insulin.

Since triglycerides are the main form of storage of excess calories in fat, recent 
research has focused on the key enzyme responsible for the synthesis of triglycerides, 
acylCoA:diacylglycerol acyltransferase in cells, or DGAT.

DGAT is a microsomal enzyme that occurs throughout mammalian tissues, and is 
also responsible for catalyzing the final step in the monoacylglycerol pathway in the 
small intestine. Recently, the gene for DGAT has been identified and cloned, enabling 
molecular studies to be performed. Northern blot analysis of DGAT mRNA levels has 
revealed that this enzyme is expressed in all tissues examined, but exists in the highest 
levels in the liver, small intestine, and adipose tissue. DGAT expression was also 
detected in skeletal muscle and brain.

The DGAT gene has been inactivated in a special strain of mice, called DGAT 
knockout (Dgat-I-) mice. These mice have been used to study the function of DGAT, and 
the implications of its absence. DGAT knockout mice, or mice lacking the DGAT gene, 
were still healthy mice, but had less adipose tissue, and lower total fat pad weights and 
body triglyceride levels. When fed a high fat diet (21% fat by weight), these mice 
maintained the same weight as the group of non-knockout mice controls fed a regular 
chow diet consisting of 4% fat by weight. The other mice consuming the high fat diet, 
experienced a 40-50% weight gain. The weight difference was primarily related to about 
a 40% decrease in total carcass triglycerides in the DGAT knockout mice.

DGAT knockout mice also exhibit higher insulin sensitivity, indicating that 
triglyceride metabolism is tightly linked with glucose metabolism.

Another interesting feature that was discovered related to DGAT knockout mice is 
that DGAT deficiency improves glucose metabolism. In addition to having potential to 
effect weight loss and energy expenditure, deficiency in DGAT appeared to alter glucose 
metabolism in the knockout mice. These mice seem to have normal levels of plasma 
-glucose and insulin, but when given a glucose load, had lower glucose and insulin levels 
than regular mice. This indicates that inhibition of DGAT enzyme could improve glucose 
metabolism. DGAT deficiency also lowered serum insulin levels in Agouti yellow mice. 
These mice are genetically obese and insulin resistant. Therefore, inhibition of DGAT 
could be an effective treatment strategy for diabetics by improving glucose metabolism.
To summarize, mice that are deficient in the DGAT enzyme are resistant to diet induced obesity and have increased insulin and leptin sensitivity. Research suggests that therapeutic inhibition of DGAT in-vivo may result in effective treatment for elevated triglycerides and the cardiovascular complications of diabetes. Therefore, an agent that inhibits DGAT, or a DGAT inhibitor would be of great utility for the treatment of diabetes, and heart disease. Inhibiting DGAT is also a fitting therapeutic strategy for a small molecule drug directed at the dyslipidaemia associated with the metabolic syndrome associated with diabetes and obesity.

Lipids are a group of fatty compounds that include phospholipids, triglycerides, and cholesterol (sterols). While cholesterol is a key constituent of cellular membranes, elevated cholesterol is a major risk factor for coronary artery disease or arteriosclerosis. Cholesterol and other fatty compounds (lipids) in the blood are insoluble, and require certain carriers that are capable of incorporating them into soluble complexes that can be transported to specific target sites. These soluble complexes are called lipoproteins.

When lipids become pathogenic, through oxidation of cholesterol, or levels of cholesterol that are above a normal healthy level, the result is atherogenesis, or the development of heart disease and its various complications. Heart disease can also be the result of a disproportionate amount of various lipid fractions such as high density lipoprotein (HDL), low density lipoprotein (LDL), and triglycerides and other fatty acids. This disproportionate balance of lipids is known as dyslipidaemia.

One of the primary drug targets for treating hypercholesterolemia, or elevated blood cholesterol, has been the inhibition of HMG-CoA reductase (3-hydroxy-3-methylglutaryl CoA reductase), the enzyme in the liver that is responsible for the synthesis of mevalonic acid, and an intermediate in the biosynthesis of sterol (cholesterol). Currently, there are many approved HMG-CoA reductase inhibitor drugs (statins), such as lovastatin, simvastatin, pravastatin, fluvastatin, and atorvastatin. There are also a few HMG-CoA reductase inhibitors identified in natural sources such as plant extracts and red yeast rice (Monascus purpureus). The benefits of statin drugs in the primary and secondary prevention of heart disease have been shown in numerous, large prospective clinical trials.

Acyl-coenzyme A cholesterol acyl transferase (ACAT) is an enzyme that esterifies cholesterol. For unesterified "free" cholesterol to be packaged into ApoB-
containing lipoproteins in the liver, it needs to be first esterified by ACAT. ACAT inhibition is believed to be antiatherogenic by accelerating cholesterol excretion by the liver, as well as by inhibiting cholesterol absorption in the intestines. ACAT inhibition also may prevent cholesteryl ester accumulation in macrophages in the arterial walls, which results in antiatherosclerosis effects. ACAT inhibition may have direct effects on the vascular system through impairment of conversion of free cholesterol to esterified cholesterol in endothelial macrophage by reducing foam cell formation.

Normally, ACAT inhibitors are thought to prevent accumulation of lipid in the arterial wall without significantly affecting plasma lipid levels. However, an agent that inhibits both ACAT and HMG CoA reductase, such as the compounds of this invention, will lower cholesterol and prevent accumulation of lipid in the arterial wall, in addition to lowering triglycerides and free fatty acids by inhibiting DGAT.


SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide a novel method of treating elevated cholesterol, triglycerides, and cardiovascular disease in an animal by inhibiting HMG-CoA reductase (3-hydroxy-3-methylglutaryl CoA reductase), ACAT (acyl-coenzyme A cholesterol acyl transferase), and DGAT (acyl CoA: diacylglycerol acyltransferase), with an extract of hops, a chalcone or flavonoid derived from the hops plant (Humulus lupulus L.), an isolated prenylchalcone or prenylflavonones, or a synthetic prenylchalcone or prenylflavonones. The prenylchalcone or prenylflavonones may be derived from hops or extracted form other botanical sources that may contain the same compounds. The primary chalcones contained in hops that are effective for inhibiting HMG CoA reductase, ACAT, and DGAT are xanthohumol A and xanthohumol B, with xanthohumol A, the preferred chalcone. Other prenylchalcones or prenylflavonones, either alone or in combination may be used.

It is an additional object of the invention to provide formulations for treating the dyslipidaemia associated with diabetes.
DETAILED DESCRIPTION OF THE INVENTION

Flavonoids are abundant throughout nature and exert a broad range of biological activities in plants and animals. There are now considered to be over 4,000 flavonoids existent in nature. Some of the biological activities of flavonoids include; anti-inflammatory, antiviral, antifungal, antibacterial, estrogenic, anti-oxidant, antiallergenic, anticarcinogenic, and antiproliferative medicinal properties.

Hops (Humulus lupulis L.) has been used for centuries as a bittering agent in the brewing of beer. Hops contains alpha acids such as humulone, co-humuone, adhumulone, and beta acids such as lupulone and co-lupulone. Hops also contains many flavonoids, the more important ones being the chalcones or prenylflavonoids; xanthohumol, isoxanthohumol, desmethylxanthohumol, 8-prenylnaringenin, and 6-prenylnaringenin. Some of these prenylflavonoids exhibit potent estrogenic activity, such as 8-prenylnaringenin, and are considered to be phytoestrogens (Reproduction; 2002; 123, 235-242). Xanthohumol is the principle flavonoid contained in hops. Xanthohumol does not exhibit estrogenic activity (Journal of Endocrinology and Metabolism; 85; 12, 4912-4915).

Xanthohumol is a yellow-orange substance with a melting point of 172 degrees C. A typical ethanol extract of hops yields about 3 mg/g (3%) of xanthohumol out of a total flavonoid content of 3.46 mg/g. Dried hop contains about 0.2 to 1.0 % by weight xanthohumol.

<table>
<thead>
<tr>
<th>Typical Flavonoid Content of an ETOH Extract of Hops</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xanthohumol</td>
</tr>
<tr>
<td>Desmethylxanthohumol</td>
</tr>
<tr>
<td>Isoxanthohumol</td>
</tr>
<tr>
<td>6-prenylnaringenin</td>
</tr>
<tr>
<td>8-prenylnaringenin</td>
</tr>
</tbody>
</table>

Xanthohumol or the other prenylchalcones or prenylflavonones can be synthesized or isolated from hops through further purification, fractionation, or separation using methods that are known to those skilled in the art, or following the procedure of
Tabata et. al.; Phytochemistry; 46, No. 4; pp. 683-687, 1997. Ethanol (EtOAc) or other solvents may be used to extract higher levels of the chalcones or flavones form hops. Supercritical carbon dioxide extractions, which do not use solvents, will tend to have much lower levels, or non-existent levels of the chalcones and flavonones. In fact these compounds are almost non-existent in standard CO2 extracts because the polyphenols (chalcones and flavonones) are virtually insolvent on carbon dioxide. Newer techniques of extraction using supercritical carbon dioxide may yield greater amounts of xanthohumol, or allow for the separation of xanthohumol and other flavonoids from other constituents of hops such as the alpha and beta acids, and essential oils and hard resins.


As used herein the term "chalcone" or "flavonone" refers to the following flavonoids; xanthohumol, xanthogalenol, desmethylxanthohumol(2',4',6',4-tetrahydroxy-3-C- prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloaxanthohumol, dehydrocycloaxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylaringenin, 8-prenylaringenin, 6-s-diprenylaringenin, 4',6'-dimethoxy-2',4'-dihydroxychalcone,4'-0-methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin.

As used herein, the term "HMG-CoA reductase inhibitor" refers to a substance that inhibits the activity of 3-hydroxy-3-methylglutaryl CoA reductase, a key enzyme in cholesterol synthesis. HMG-CoA reductase inhibition can be measured in-vitro in a suitable cell line such as HeG2 cells or rat liver microsomes.

As used herein, the term "ACAT inhibitor" refers to a substance that inhibits the activity of acyl-coenzyme A cholesterol acyl transferase, an enzyme that esterifies cholesterol.

As used herein, the term "DGAT inhibitor" refers to a substance that inhibits the activity of diacylglycerol acyltransferase, an enzyme involved in hypertriglyceridemia, or high levels of triglycerides and fatty acids, as well as fatty liver and obesity.

One method of determining if a compound is a DGAT inhibitor is the DGAT assay using rat liver microsomes. This assay was used by Tabata et. al. (Phytochemistry;
Xanthohumol A and xanthohumol B inhibited DGAT activity with IC50 values of 50.3 and 194 pM respectively. The xanthohumols also showed preferential inhibition of triacylglycerol formation in intact Raji cells. Raji cells are intact cells and are used to assay for lipid formation. The Raji assay indicated that xanthohumol inhibited DGAT activity specifically in human cells.

Example 1

Human hepatopblastoma (HepG2) cells can be used to screen compounds for HMG CoA reductase inhibition activity. HepG2 cells can be obtained from the American Type Culture Collection (Rockville, MD) and grown as described in; Evans et al., J. Biol. Chem. 267: 10743-10751. These cells can be plated in either 100 mm or in 6-well (35-mm) culture plates from Falcon Scientific (VWR, Missisauga, ON) and maintained in minimal essential medium containing 5% human lipoprotein-deficient serum (LPDS). The appropriate concentrations (ranging from 0, 0.5, 1, 5, 10, and 50 pg/ml) of xanthohumol solubilized in dimethyl sulfoxide (DMSO) are added to the dishes and incubated for 24 hours. Duplicate dishes of HepG2 cells will be used for each time point or concentration of compound. Apo B secretion and triglyceride synthesis catalyzed by diacylglycerol acyltransferase (DGAT), primary processes associated with the secretion of LDL can be measured. Modulation of apoB secretion from HepG2 cells via HMG-CoA reductase inhibition by xanthohumol will indicate a significant decrease in apoB.

Incorporation of carbon 14 labeled acetic acid or carbon 14 labeled oleic acid into cellular lipids will be performed from 0 h to 5 h or from 19 h to 24 h after the addition of xanthohumol at different concentrations. This protocol will provide information about the inhibition of HMG-CoA reductase over time and will determine if differences in apoB secretion are due to a difference in the metabolism or clearance of inhibitor from the hepatocyte, resulting in an attenuation of HMG-CoA reductase inhibiton at later time points.

From this assay system, it can be determined that oleate-induced stimulation of apo B secretion was significantly decreased. This can be determined by radiolabeling 3H-oleic acid and measuring its incorporation into triglycerides, because fatty acids are
synthesized into triglycerides. The data is expected to indicate that xanthohumol inhibits DGAT activity resulting in decreased synthesis of triglycerides. In addition, it will be observed that carbon 14 labeled oleic acid incorporation into cholesteryl ester (CE) will be decreased by xanthohumol during the incubation.

Example 2

Inhibition of hepatic ACAT will also be demonstrated in HEPG2 cells as evidenced by incorporation of carbon 14 labeled oleic acid or carbon 14 labeled acetic acid into cellular lipids by incubating xanthohumol in the assay, and measuring the incorporation of oleic acid into cholesteryl ester (CE) or phospholipid. Results will show a significant reduction in incorporation of radiolabeled acetate or oleate into cholesteryl ester. In other words, xanthohumol decreased cholesterol esterification. This is an indication that xanthohumol is an ACAT inhibitor.

DGAT inhibition may also be involved in improved glucose metabolism, which has implications for the treatment of diabetes. Recent research indicates that there are two forms of DGAT, DGAT1 and DGAT2, or two distinct DGAT genes.

Glucose (carbohydrate) and insulin each have effects on DGAT, glucose preferentially enhances DGAT1 mRNA expression, and insulin specifically increases the level of DGAT2 mRNA. Therefore, glucose and insulin help regulate the DGAT enzyme.

The prenylchalcones and prenylflavones have potential in the treatment of elevated cholesterol and other dyslipidaemias. By helping to control or lower cholesterol, the esterification of cholesterol, and triglyceride metabolism, as well as glucose, and insulin resistance, these compounds could be effectively used as broad spectrum cardiovascular agents.

It is anticipated that the HMG CoA reductase inhibitor from hops should inhibit the enzyme by at least 10%, and preferably by 25-75%. Complete inhibition of the enzyme may not be desirable due to potential unknown side-effects. By comparison, Atorvastatin inhibits HMG CoA reductase in HepG2 cells by about 96%. ACAT inhibition by xanthohumol in HepG2 cells is expected to be from 10-75%.

The dose of the prenylchalcone of flavonone is expected to be at least 5 to 1,000 mg. The dose of pure xanthohumol is expected to be lower than an extract of hops.
containing 3-5% xanthohumol. If an extract of hops is used, the dose would be 25-3,000 mg due to the low amount of xanthohumol. If purified xanthohumol is used, the dose may be from 5-1,000 mg, but more preferably about 5-500 mg.

Preferably, a dose of prenylchalcone such as xanthohumol would achieve a blood level of from at least 0.01 to 0.5 µg/ml. Or a blood level concentration of at least 10 to 200 µM.

The preferred embodiments may also employ conjugates of prenylchalcones or flavonones, or conjugates of xanthohumol.

Conjugates as used herein may mean prenylchalcones such as xanthohumol covalently bound or conjugated to a member selected from the group consisting of amino acids, sulfates, succinate, acetate, mono- or di-saccharides, or glutathione. A preferred conjugate would be a succinate such as xanthohumol succinate.

High concentrations of prenylchalcones or flavonones are expected to be contained in solvent based extracts of hops that result in high viscosity fluids (resin type materials) which can be further purified. This high viscosity extract can be combined with a pharmaceutically acceptable oil such as olive oil or soy phospholipids (phosphatidylcholine) and encapsulated in a soft gel capsule, or placed on a suitable pharmaceutical carrier to make a dry powder. If incorporated into a phospholipid complex, methods such as are described in U. S. Patent numbers 4,764,508; 4,963,527; and 5,043,323 maybe used. Suitable carriers are maltodextrin, silica or salts of silica, talc, metal stearates, fibers such as guar gum, cellulose, modified cellulose (cellulose ethers), pectin, acacia, xanthum gum, or proteinaceous materials such as sodium casseinate, or casein, diatomacious earth, fullers earth, and gelatin. Beadlets of gelatin can be formed by heating a cooling the extract with gelatin to form beadlets using methods known to those skilled in the art. These carriers can be used individually or together in any number of combinations.

Pharmaceutical dosage forms such as capsules, tablets, or suppositories, can be made. Various excipients, such as cellulose or cellulose ethers, may be use to produce sustained-release of the active compound. The prenylchalcones and flavonones such as xanthohumol may also be formulated into a food, liquid drink, lozenge, gum or snack item.
According to the preferred embodiments, the animal may be selected from the group consisting of humans, non-humans, primates, dogs, cats, birds, horses, or other warm-blooded animals.

While the present invention is described above in connection with the preferred or illustrative embodiments, those embodiments are not intended to be exhaustive or limiting of the invention, but rather, the invention is intended to cover any alternatives, modifications or equivalents that may be included within its scope as defined by the appended claims.

What is claimed is:
CLAIMS

1. A method of treating or preventing diseases associated with elevated blood cholesterol or dyslipidaemia in an animal, comprising: administering to said animal, an effective amount of hops as an active ingredient together with a pharmaceutically acceptable carrier.

2. The method of claim 1, wherein the hops contains an amount of prenylated chalcones or prenylated flavones that inhibits HMG-CoA reductase by at least 10%.

3. The method of claim 2, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4'-O-methylxanthohumol, 6'-geranyl naringenin, 8-geranyl naringenin and combinations thereof.

4. The method of claim 3, wherein the prenylated chalcone is xanthohumol.

5. A method of inhibiting ACAT in a subject, comprising administering hops to the subject.

6. The method of claim 5, wherein the hops contains an amount of prenylated chalcones or prenylated flavones that inhibits the ACAT by at least 10%.

7. The method of claim 6, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-
5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-
prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4'-O-
methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin, and combinations
thereof.

8. The method of claim 7, wherein the prenylated chalcone is xanthohumol.

9. The method of claim 8, wherein the xanthohumol is combined with a
pharmaceutically acceptable carrier.

10. The method of claim 9, wherein the dose of xanthohumol is from 5-1,000
mg.

11. The method of claim 10, wherein the dose of xanthohumol is from 5-750
mg.

12. The method of claim 11, wherein the dose of xanthohumol is 5-500 mg.

13. A method of treating hyperlipidemia, coronary heart disease,
arteriosclerosis, atherosclerosis, angina pectoris, or stroke comprising administering to an
animal in need thereof an effective amount of an extract of hops containing prenylated
chalones or prenylated flavonones.

14. The method of claim 13, wherein the prenylated chalones or prenylated
flavones are selected from the group consisting of xanthohumol, xanthogalenol,
desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-
tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol,
dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-
5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenynaringenin, 8-
prenynaringenin, 6,8-diprenynaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4'-O-
methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin, and combinations
thereof.
15. The method of claim 14, wherein the prenylated chalcone comprises xanthohumol.

16. The method of claim 15, wherein the xanthohumol is administered in a single dose of 5-1,000 mg with a pharmaceutical carrier.

17. The method of claim 15, wherein the xanthohumol is administered in a single dose of 5-500 mg with a pharmaceutical carrier.

18. A method of treating dyslipidaemia associated with diabetes in a subject, comprising administering to the subject an extract of hops.

19. The method of claim 18, wherein the extract of hops contains prenylated chalcones.

20. The method of claim 19, wherein the prenylated chalcone comprises xanthohumol.

21. A method of lowering triglycerides in an animal, comprising administering to the animal an extract of hops.

22. A method of lowering serum cholesterol in an animal, comprising administering to the animal an extract of hops.

23. The method of claim 21, wherein the extract of hops comprises xanthohumol.

24. The method of claim 22, wherein the extract of hops comprises xanthohumol.
25. A method of treating elevated blood cholesterol or dyslipidaemia, 
   comprising administering to an animal an effective amount of a hops extract.

26. The method of claim 25, wherein the hops extract includes prenylated 
   chalcones or prenylated flavones.

27. The method of claim 26, wherein the prenylated chalcones or prenylated 
   flavones are selected from the group consisting of xanthohumol, xanthogalenol, 
   desmethylxanthohumol (2',4',6',4'-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4'- 
   tetrahydroxy-S'-C-geranylchalcone, dehydrocycloxanthohumol, 
   dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O- 
   5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8- 
   prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4'-dihydroxychalcone, 4'-O- 
   methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin, and combinations 
   thereof.

28. The method of claim 26, wherein the prenylated chalcone or prenylated 
   flavones is xanthohumol.

29. The method of claim 28, wherein the xanthohumol is administered in a 
   single dose of from 5 mg to 1000 mg.

30. The method of claim 28, wherein the xanthohumol is administered in a 
   single dose of from 5 mg to 750 mg.

31. The method of claim 28, wherein the xanthohumol is administered in a 
   single dose of from 5 mg to 500 mg.

32. The method of claim 28, wherein the administration of xanthohumol 
   provides a blood level of 0.01 to 0.5 µg/ml in the animal.
33. The method of claim 28, wherein the administration of xanthohumol provides a blood level concentration of 10 to 200 µM in the animal.

34. The method of claim 26, wherein the prenylated chalcones or prenylated flavones include a conjugate of xanthohumol.

35. The method of claim 34, wherein the conjugate of xanthohumol is xanthohumol succinate.

36. The method of claim 25, wherein the hops extract is administered in dosage forms selected from the group consisting of capsules, tablets, and suppositories.

37. The method of claim 25, wherein the hops extract is administered with an acceptable pharmaceutical carrier.

38. The method of claim 25, wherein the animal is a human.

39. A method of treating hyperlipidaemia, comprising administering to an animal an effective amount of a hops extract.

40. The method of claim 39, wherein the hops extract includes prenylated chalcones or prenylated flavones.

401. The method of claim 40, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-S'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4'-O-methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin, and combinations thereof.
42. The method of claim 41, wherein the prenylated chalcone or prenylated flavones is xanthohumol.

43. The method of claim 42, wherein the xanthohumol is administered in a single dose of from 5 mg to 1000 mg.

44. The method of claim 42, wherein the xanthohumol is administered in a single dose of from 5 mg to 750 mg.

45. The method of claim 42, wherein the xanthohumol is administered in a single dose of from 5 mg to 500 mg.

46. The method of claim 42, wherein the administration of xanthohumol provides a blood level of 0.01 to 0.5 µg/ml in the animal.

47. The method of claim 42, wherein the administration of xanthohumol provides a blood level concentration of 10 to 200 µM in the animal.

48. The method of claim 40, wherein the prenylated chalcones or prenylated flavones includes a conjugate of xanthohumol.

49. The method of claim 48, wherein the conjugate of xanthohumol is xanthohumol succinate.

50. The method of claim 39, wherein the hops extract is administered in dosage forms selected from the group consisting of capsules, tablets, and suppositories.

51. The method of claim 39, wherein the hops extract is administered with an acceptable pharmaceutical carrier.

52. The method of claim 39, wherein the animal is a human.
53. A use of hops in preparation of a medicament for treating or preventing
diseases associated with elevated blood cholesterol or dyslipidaemia in an animal,
wherein the medicament comprises an effective amount of hops as an active ingredient
together with a pharmaceutically acceptable carrier.

54. The use of claim 53, wherein the hops contains an amount of prenylated chalcones or prenylated flavones that inhibits HMG-CoA reductase by at least 10%.

55. The use of claim 54, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4-O-methylxanthohumol, 6-geranyl naringenin, 8-geranyl naringenin and combinations thereof.

56. The use of claim 55, wherein the prenylated chalcone is xanthohumol.

57. A use of hops in preparation of a medicament for inhibiting ACAT in a subject, wherein the medicament comprises an effective amount of hops as an active ingredient.

58. The use of claim 57, wherein the hops contains an amount of prenylated chalcones or prenylated flavones that inhibits the ACAT by at least 10%.

59. The use of claim 58, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-0-
5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenynaringenin, 8-prenynaringenin, 6,8-diprenynaringenin, 4',6'-dimethoxy-2',4-dihydroxylchalcone, 4'-O-methylxanthohumol, 6-geranylnaringenin, 8-geranylnaringenin, and combinations thereof.

60. The use of claim 59, wherein the prenylated chalcone is xanthohumol.

61. The use of claim 60, wherein the xanthohumol is combined with a pharmaceutically acceptable carrier.

62. The use of claim 61, wherein the medicament comprises xanthohumol in an amount from 5-1,000 mg.

63. The use of claim 62, wherein the medicament comprises xanthohumol in an amount from 5-750 mg.

64. The use of claim 63, wherein the medicament comprises xanthohumol in an amount from 5-500 mg.

65. A use of hops in preparation of a medicament for treating hyperlipidemia, coronary heart disease, arteriosclerosis, atherosclerosis, angina pectoris, or stroke, wherein the medicament comprises an effective amount of an extract of hops containing prenylated chalcones or prenylated flavones.

66. The use of claim 64, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6,4'-tetrahydroxy-3-pC-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-5'C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenynaringenin, 8-prenynaringenin, 6,8-diprenynaringenin, 4',6'-dimethoxy-2',4-dihydroxylchalcone, 4'-O-
methylxanthohumol, 6-geranyl\textit{naringenin}, 8-geranyl\textit{naringenin}, and combinations thereof.

67. The use of claim 66, wherein the prenylated chalcone comprises \textit{xanthohumol}.

68. The use of claim 67, wherein the \textit{xanthohumol} is present in the medicament of from 5mg to 1000 mg with a pharmaceutical carrier.

69. The use of claim 67, wherein the \textit{xanthohumol} is present in the medicament of from 5mg to 500 mg with a pharmaceutical carrier.

70. A use of hops in preparation of a medicament for treating dyslipidaemia associated with diabetes in a subject, wherein the medicament comprises an extract of hops.

71. The use of claim 70, wherein the extract of hops contains prenylated chalcones.

72. The use of claim 71, wherein the prenylated chalcone comprises \textit{xanthohumol}.

73. A use of hops in preparation of a medicament for lowering triglycerides in an animal, wherein the medicament comprises an extract of hops.

74. A use of hops in preparation of a medicament for lowering serum cholesterol in an animal, wherein the medicament comprises an extract of hops.

75. The use of claim 73, wherein the extract of hops comprises \textit{xanthohumol}.

76. The use of claim 74, wherein the extract of hops comprises \textit{xanthohumol}.
77. A use of hops in preparation of a medicament for treating elevated blood cholesterol or dyslipidaemia in an animal, wherein the medicament comprises an effective amount of a hops extract.

78. The use of claim 77, wherein the hops extract includes prenylated chalcones or prenylated flavones.

79. The use of claim 78, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2',4',6',4-tetrahydroxy-3-C-prenylchalcone), 2',4',6',4-tetrahydroxy-3'-C-geranylchalcone, dehydrocycloxanthohumol, dehydrocycloxanthohumol hydrate, 5'-prenylxanthohumol, tetrahydroxanthohumol, 4'-O-5'-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-prenylnaringenin, 6,8-diprenylnaringenin, 4',6'-dimethoxy-2',4-dihydroxychalcone, 4-O-methylxanthohumol, 6-geranyl naringenin, 8-geranyl naringenin, and combinations thereof.

80. The use of claim 78, wherein the prenylated chalcone or prenylated flavones is xanthohumol.

81. The use of claim 80, wherein the xanthohumol is present in the medicament of from 5 mg to 1000 mg.

82. The use of claim 80, wherein the xanthohumol is present in the medicament of from 5 mg to 750 mg.

83. The use of claim 80, wherein the xanthohumol is present in the medicament of from 5 mg to 500 mg.

84. The use of claim 80, wherein the medicament is formulated to provide a blood level of 0.01 to 0.5 µg/ml of xanthohumol in the animal.
85. The use of claim 80, wherein the medicament is formulated to provide a blood level concentration of 10 to 200 µM of xanthohumol in the animal.

86. The use of claim 78, wherein the prenylated chalcones or prenylated flavones include a conjugate of xanthohumol.

87. The use of claim 86, wherein the conjugate of xanthohumol is xanthohumol succinate.

88. The use of claim 77, wherein the medicament is in dosage forms selected from the group consisting of capsules, tablets, and suppositories.

89. The use of claim 77, wherein the medicament further comprises an acceptable pharmaceutical carrier.

90. The use of claim 77, wherein the animal is a human.

91. A use of hops in preparation of a medicament for treating hyperlipidaemia, wherein the medicament comprises an effective amount of a hops extract.

92. The use of claim 91, wherein the hops extract includes prenylated chalcones or prenylated flavones.

93. The use of claim 92, wherein the prenylated chalcones or prenylated flavones are selected from the group consisting of xanthohumol, xanthogalenol, desmethylxanthohumol (2’,4’,6’,4-tetrahydroxy-3-C-prenylchalcone), 2’,4’,6’,4-tetrahydroxy-3’-C-geranylchalcone, dehydrocyclophanthohumol, dehydrocyclophanthohumol hydrate, 5’-prenylxanthohumol, tetrahydroxanthohumol, 4’-O-S’-C-diprenylxanthohumol, chalconaringenin, isoxanthohumol, 6-prenylnaringenin, 8-prenylnaringenin, 6,8-diprenylnaringenin, 4’-6’-dimethoxy-2’,4-dihydroxychalcone, 4’-O-methylxanthohumol, 6-geranylringenin, 8-geranylringenin, and combinations thereof.
94. The use of claim 93, wherein the prenylated chalcone or prenylated flavones is xanthohumol.

95. The use of claim 94, wherein the xanthohumol is present in the medicament of from 5 mg to 1000 mg.

96. The use of claim 94, wherein the xanthohumol is present in the medicament of from 5 mg to 750 mg.

97. The use of claim 94, wherein the xanthohumol is present in the medicament of from 5 mg to 500 mg.

98. The use of claim 94, wherein the medicament is formulated to provide a blood level of 0.01 to 0.5 µg/ml of xanthohumol in the animal.

99. The use of claim 94, wherein the medicament is formulated to provide a blood level concentration of 10 to 200 µM of xanthohumol in the animal.

100. The use of claim 92, wherein the prenylated chalcones or prenylated flavones includes a conjugate of xanthohumol.

101. The use of claim 100, wherein the conjugate of xanthohumol is xanthohumol succinate.

102. The use of claim 91, wherein the medicament is in dosage forms selected from the group consisting of capsules, tablets, and suppositories.

103. The method of claim 91, wherein the medicament further comprises an acceptable pharmaceutical carrier.

104. The method of claim 91, wherein the animal is a human.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

A61K 31/12(2006.01)j, A61K 36/185(2006.01)j, A61P 3/06(2006.01)j

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 8 as above

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN(REG, CAplus), PubMed

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>TABATA, NORIKO et al, 'Xanthohumols, diacylglycerol acyltransferase inhibitors, from Humulus lupulus', Phytochemistry, 46(4), pp 683-687 (1997) See p 683(left column) and p 684 (figure 1)</td>
<td>53-104</td>
</tr>
<tr>
<td>A</td>
<td>NOZAWA, HAJIME, 'Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-Ay mice', Biochemical and Biophysical Research Communications, 336(3), pp 754-761 (2005) See the whole document</td>
<td>53-104</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C

See patent family annex

* Special categories of cited documents
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier application or patent but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

17 JUNE 2008 (17.06.2008)

Date of mailing of the international search report

18 JUNE 2008 (18.06.2008)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, 139 Seonsa-ro, Seogu, Daejeon 302-701, Republic of Korea

Authorized officer

KIM, YONG

Facsimile No 82-42-472-7140

Telephone No 82-42-481-8164

Form PCT/ISA/210 (second sheet) (April 2007)
International search report No.
PCT/ISA/210 (continuation of first sheet (2)) (April 2007)

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [x] Claims Nos. 1-52 because they relate to subject matter not required to be searched by this Authority, namely:
   Claims 1-52 pertain to methods for treatment of the human or animal body by therapy, as well as prevention method, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39 (iv) of the Regulations under the PCT, to search.

2. [ ] Claims Nos. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically.

3. [ ] Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6 4(a).

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [x] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [x] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [x] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.

Remark on Protest

[ ] The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

[ ] The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.

[ ] No protest accompanied the payment of additional search fees.